SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

Oxford Nanopore Technologies plc ONTTF OTC

Other OTC • Healthcare • Biotechnology • GB • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Oxford Nanopore Technologies plc (ONTTF) is a Biotechnology company in the Healthcare sector, currently trading at $1.53. It has a SharesGrow Score of 45/100, indicating a mixed investment profile with 1 out of 7 criteria passed.

Financials: revenue is $224M, +5.2%/yr average growth. Net income is $145M (loss), growing at -21.2%/yr. Net profit margin is -64.9% (negative). Gross margin is 58.6% (-3.7 pp trend).

Balance sheet: total debt is $41M against $463M equity (Debt-to-Equity (D/E) ratio 0.09, conservative). Current ratio is 3.56 (strong liquidity). Debt-to-assets is 6.7%. Total assets: $622M.

Analyst outlook: 3 / 3 analysts rate ONTTF as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 40/100 (Partial), Past 0/100 (Fail), Health 67/100 (Partial), Moat 61/100 (Partial), Future 100/100 (Pass), Income 10/100 (Fail).

ONTTF SharesGrow Score Overview

56/100

SharesGrow Score

Above average fundamentals

View full scorecard →

VALUE 0/100

Valuation — P/E, PEG, Forward PEG

GROWTH 40/100

Financials — average growth

PAST 0/100

strong — trend

HEALTH 67/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 61/100

Gross margin is + market cap

FUTURE 100/100

Analyst outlook — as buy

INCOME 10/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — ONTTF

No analyst coverage available for this stock.

ONTTF: +5.2%/yr revenue is, -21.2%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

No analyst coverage available for this stock.

Balance sheet ONTTF: Debt-to-Equity (D/E) ratio 0.09 (conservative), Current ratio is 3.56 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

ONTTF: Gross margin is 58.6% (-3.7 pp trend), $1B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 61/100. ≥ 70 = Pass.

View details →

Analyst outlook: 3 / 3 analysts rate ONTTF as buy (100%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.

View details →

ONTTF: Net profit margin is -64.9%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

Market Data

52-Week Range1.24-3.34

Volume133

Avg Volume (30D)19.17K

Market Cap$1.48B

Beta (1Y)0.88

Share Statistics

EPS (TTM)-0.15

Shares Outstanding$960.99M

IPO Date2021-10-15

Employees1,382

CEOFrancis Albert Luc Van Parys

Financial Highlights & Ratios

Revenue (TTM)$223.86M

Gross Profit$131.28M

EBITDA$-105.48M

Net Income$-145.18M

Operating Income$-155.27M

Total Cash$255.26M

Total Debt$41.49M

Net Debt$-139.58M

Total Assets$622.4M

Price / Earnings (P/E)-10.2

Price / Sales (P/S)6.63

Analyst Forecast

Rating ConsensusBuy

Analysts Covering3

Buy 100% Hold 0% Sell 0%

Company Info

CountryGB

ExchangeOther OTC

CurrencyUSD

ISINGB00BP6S8Z30

Price Chart

ONTTF

Oxford Nanopore Technologies plc ↗ · Other OTC

Healthcare • Biotechnology

1.24 52WK RANGE 3.34

People Also View

Innovent Biologics, Inc.

Genscript Biotech Corporation

Nurix Therapeutics, Inc.

Lineage Cell Therapeutics, Inc.

Quantum-Si incorporated

MediciNova, Inc.

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message